Had to do a double-take when I noticed that Ranbaxy Labs has hired former NYC mayor Rudy Giuliani to help defend it against allegations of quality problems with drugs sold in the U.S (click here for more).
Ironically, perhaps, to some, Giuliani's last gig with pharma involved ranting against foreign threats and the insecurity of the U.S. pharma supply.
Here's the news directly from the source:Gurgaon, India, September 18, 2008 -- Ranbaxy Laboratories Ltd., today announced that they have retained the services of former New York City Mayor Rudy Giuliani and Giuliani Partners to provide advice and review compliance issues related to the recent United States Food and Drug Administration letters and Import Advisory.
In announcing the addition of Mayor Giuliani, Ranbaxy reiterated its commitment to work cooperatively with the FDA to address the Import Advisory and put into place measures which will allow its products identified on the Advisory to be released into the US marketplace.
As the FDA stated, all drugs manufactured by Ranbaxy have repeatedly tested safe and effective with no adverse incidents reported. Ranbaxy is committed to a swift resolution to address these issues and to continuing to supply the global marketplace with safe and effective pharmaceuticals.
Ranbaxy is one of the world’s largest manufacturers of generic drugs, with production facilities in the United States and India.
Ranbaxy Laboratories Limited, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies," resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 11 countries
